Havemeyer Place’s BridgeBio Pharma BBIO Stock Holding History

Havemeyer Place’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$648K	Buy	8,696 +437	+5%	+$30.6K	0.06%	371
2026 Q1	$613K	Buy	+8,259	New	+$599K	0.07%	378

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Havemeyer Place's BBIO Position: Q2 2026 in Review

Havemeyer Place increased its BridgeBio Pharma (BBIO) stake by 5.3% in Q2 2026, buying an estimated $30.6K and bringing the position to 8,696 shares worth $648K. The position accounts for 0.06% of the portfolio, ranked #371.

Havemeyer Place first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Havemeyer Place held 8,696 shares of BridgeBio Pharma worth $648K as of Q2 2026.
Havemeyer Place bought 437 BridgeBio Pharma shares in Q2 2026, an estimated $30.6K.
BridgeBio Pharma made up 0.06% of Havemeyer Place's portfolio in Q2 2026, its #371 holding.
Havemeyer Place first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Havemeyer Place's 13F filing for Q2 2026, filed 13 Aug 2026.